Internal Reference Number: FOI_7667
Date Request Received: 12/01/2024 00:00:00
Date Request Replied To: 31/01/2024 00:00:00
This response was sent via: By Email
Request Summary: biologic medicines in dermatology
Request Category: Researcher
| Question Number 1: I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following two questions: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: • Adalimumab - Humira - 15 • Adalimumab Biosimilar - <5 • Apremilast - <5 • Bimekizumab - <5 • Brodalumab - 6 • Certolizumab - <5 • Deucravacitinib - 0 • Dimethyl fumarate - 0 • Etanercept - Enbrel - 0 • Etanercept Biosimilar - 0 • Guselkumab - 25 • Infliximab - Remicade - 0 • Infliximab Biosimilar - 0 • Ixekizumab - 6 • Risankizumab - 6 • Secukinumab - <5 • Tildrakizumab - 7 • Ustekinumab - <5 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following: • Ciclosporin • Methotrexate - any form and strength • Methotrexate injections 15mg and above | |
| Answer To Question 2: Ciclosporin- 5 patients Methotrexate- 10 patients none on injections of methotrexate- all oral meds | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
